Edition:
India

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

25.56USD
24 Apr 2017
Change (% chg)

$0.70 (+2.82%)
Prev Close
$24.86
Open
$25.12
Day's High
$25.69
Day's Low
$25.10
Volume
2,923,321
Avg. Vol
1,926,384
52-wk High
$25.69
52-wk Low
$19.59

BSX.N

Chart for BSX.N

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health,... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $34,990.91
Shares Outstanding(Mil.): 1,368.97
Dividend: --
Yield (%): --

Financials

MEDIA-Abbott, Medtronic, Boston Scientific to recall new generation stents from India - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

24 Apr 2017

BRIEF-Boston Scientific initiates global study to assess sudden cardiac arrest prevention therapy

* Boston Scientific initiates global study to assess sudden cardiac arrest prevention therapy in patients with diabetes who have previously experienced a heart attack

19 Apr 2017

Boston Scientific to expand in Europe with Symetis buy

Boston Scientific Corp on Thursday agreed to buy Swiss medical device maker Symetis SA for $435 million, looking to bolster its presence in Europe after recalling a range of heart valves in the region.

30 Mar 2017

UPDATE 3-Boston Scientific to expand in Europe with Symetis buy

* Symetis' Acurate devices complementary to Boston Scientific's Lotus valves

30 Mar 2017

BRIEF-Symetis, Boston Scientific reach $435 mln purchase agreement

* Symetis and Boston Scientific reach USD 435 million purchase agreement

30 Mar 2017

BRIEF-Boston Scientific agrees to acquire Symetis for $435 mln

* Boston Scientific Corp - deal for $435 million in up-front cash

30 Mar 2017

Boston Scientific to acquire Symetis for $435 mln

March 30 Boston Scientific Corp said on Thursday it would buy privately-held Swiss medical device maker Symetis SA for $435 million to expand its business of making minimally invasive heart devices.

30 Mar 2017

BRIEF-Boston Scientific CEO Michael Mahoney's FY 2016 total compensation was $12 mln vs $11.6 mln in FY 2015

* CEO Michael Mahoney's FY 2016 total compensation was $12.0 million versus $11.6 million in FY 2015 - sec filing Source text (http://bit.ly/2ny4bpM) Further company coverage:

29 Mar 2017

U.S. medtech shares gain as investors seek shelter from drug price debate

NEW YORK, March 13 Investors are seeking shelter in shares of U.S. medical device and supply companies, encouraged by their solid growth prospects and wary that U.S. President Donald Trump's criticism of drug prices makes owning pharmaceutical and biotechnology stocks risky.

14 Mar 2017

BRIEF-German patent court issues initial decision

* District court in Germany ruled that Boston Scientific's lotus valve infringes one of co's patents for transcatheter aortic valves

09 Mar 2017

More From Around the Web

Competitors

Earnings vs. Estimates